CLAIMS

1. A pharmaceutical composition comprising the nordihydroguaiaretic acid (NDGA) derivative tetra-O-methyl nordihydroguaiaretic acid (M4N) and sorafenib.

2. Use of the pharmaceutical composition of claim 1 in the manufacture of a medicament for treating a disease or disorder associated with a neoplastic disease in a subject.

3. The use of claim 2 wherein the subject is a human, cat, dog or mouse.

4. The use of either of claim 2 or 3, wherein the neoplastic disease is a tumor and/or its micro and macrometastases.

5. The use of claim 4, wherein the tumor is a solid tumor, a hematological tumor, or wherein the tumor and/or its micro and macrometastases is selected from the group consisting of breast cancer, prostate cancer, pancreatic cancer, colon cancer, hepatoma, glioblastoma, ovarian cancer, leukemia, Hodgkin's lymphoma and multiple myeloma.

6. Use of the pharmaceutical composition of claim 1 in the manufacture of a medicament for preventing or inhibiting a tumor and/or its micro and macrometastatic growth in a subject.

7. The use of claim 6 wherein the subject is a human, cat, dog or mouse.

8. The use of claim 6 or 7, wherein the tumor is a solid tumor, a hematological tumor, or wherein the tumor is selected from the group consisting of breast cancer, prostate cancer, pancreatic cancer, colon cancer, hepatoma, glioblastoma, ovarian cancer, leukemia, Hodgkin's lymphoma and multiple myeloma.

9. The use of any of claims 6 to 8, wherein the pharmaceutical composition comprises an additional therapeutic agent.

10. The pharmaceutical composition of claim 1 for use as a medicament.